ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc

Bullboard Posts

Post by xena555on Dec 07, 2018 12:21pm

104 Views

Post# 29082853

consolidation and U.S. listing

just a warning that the concept of rolling up shares and listing on the NASDAQ isn't always the answer.....look at Diamedica (DMA.cn, and DMAC.Q)- they rolled up their shares 20-1 on Nov 15, listed in the U.S. and did a raise today at $4.00 us$.....stock is trading underwater, shares were $9.10 (canadian) when they made the announcement, now trading at $4.88.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload